Mycoplasma Bovis

Mycoplasma bovis is an emerging and economically significant bacterial pathogen affecting cattle worldwide. This unique organism causes a spectrum of disease manifestations including chronic pneumonia, arthritis, ear infections, mastitis, and various other syndromes that can devastate individual animals and herds. Unlike conventional bacteria, mycoplasmas lack a cell wall, making them inherently resistant to many commonly used antimicrobials and presenting unique challenges for treatment and control.

Mycoplasma bovis infection affects cattle of all ages but demonstrates distinct disease patterns across different populations. Young dairy calves are particularly susceptible to ear infections and pneumonia, while feedlot cattle commonly develop chronic pneumonia unresponsive to standard respiratory disease treatments. Adult dairy cows primarily experience mycoplasma mastitis, a highly contagious form of udder infection that can spread rapidly through milking equipment and procedures. The organism has been isolated from cattle on every continent where cattle are raised commercially, with prevalence increasing significantly over recent decades.

The economic impact of Mycoplasma bovis extends across all cattle sectors and encompasses both direct disease losses and control program costs. Chronic pneumonia cases consume substantial treatment resources while often failing to respond adequately, resulting in poor growth performance and eventual mortality or salvage. Arthritis cases in young animals may require euthanasia due to severe lameness and poor prognosis. Mycoplasma mastitis creates serious herd health problems as infected cows shed enormous numbers of organisms that readily infect other cows, leading to outbreak situations requiring aggressive culling to control spread.

Management and control of Mycoplasma bovis presents significant challenges due to the organism's characteristics and behavior. Treatment success rates remain disappointing compared to other bacterial pathogens, and no effective commercial vaccine is currently available in most regions. Control programs focus heavily on identification and removal of infected animals, biosecurity to prevent introduction, and careful management of calving and calf-rearing environments to limit transmission to susceptible young animals. Ongoing research continues to seek improved diagnostic methods, treatment options, and vaccine development.

Mycoplasma bovis is a small, cell wall-deficient bacterium belonging to the class Mollicutes. The absence of a cell wall fundamentally affects both the organism's biology and its response to antimicrobial therapy, as many antibiotics target cell wall synthesis. Mycoplasmas are among the smallest self-replicating organisms known and have highly reduced genomes compared to conventional bacteria. The organism survives in the host through sophisticated immune evasion mechanisms including antigenic variation, where surface proteins continuously change to escape immune recognition, allowing chronic persistent infections to develop.

No genetic predisposition to Mycoplasma bovis infection has been established in cattle, as the organism can infect animals of any breed or genetic background. However, individual variation in immune competence affects the likelihood of clinical disease development following exposure. Some animals appear to clear infections or maintain subclinical carrier status while others develop severe disease manifestations. Host factors including age, concurrent infections, nutritional status, and stress levels influence disease outcomes more than genetics.

Environmental and management factors strongly influence Mycoplasma bovis transmission and disease expression. The organism spreads through direct contact, aerosol transmission, and contaminated milk or colostrum, making close-contact situations in housing, feeding areas, and milking parlors high-risk environments for transmission. Commingling cattle from multiple sources, purchasing animals from herds with unknown mycoplasma status, and feeding unpasteurized waste milk or colostrum to calves represent major introduction and amplification pathways. Poor ventilation and overcrowding in calf housing facilities increase respiratory disease risk.

Risk factors for Mycoplasma bovis disease include young age, recent stress events, concurrent respiratory infections, and exposure to shedding animals. Calves fed unpasteurized milk from cows with mycoplasma mastitis face high infection risk. Animals undergoing transport, weaning, or entry into feedlots experience stress-related immunosuppression that increases susceptibility. Prior infection with viral respiratory pathogens damages respiratory defenses and creates conditions favorable for mycoplasma proliferation. Operations that frequently introduce cattle without quarantine or testing face ongoing introduction risk.

The pathophysiology of Mycoplasma bovis involves several mechanisms that contribute to chronic, treatment-resistant disease. Upon colonizing respiratory epithelium, the organism damages ciliated cells that normally clear pathogens from airways. The bacteria induce host inflammatory responses that cause tissue damage while simultaneously evading immune clearance through antigenic variation and other mechanisms. In joints and other tissues, mycoplasmas trigger persistent inflammation with progressive structural damage. The organism can also invade and persist within host cells, protecting it from both immune responses and antimicrobial drugs and enabling long-term carrier states.

Early warning signs of Mycoplasma bovis infection often develop insidiously, distinguishing it from the acute onset typical of other respiratory pathogens. Initial respiratory disease may present with mild coughing, slight nasal discharge, and modest depression that owners or caregivers might dismiss as minor illness. Fever is frequently low-grade or intermittent rather than the high persistent fever seen with Mannheimia haemolytica. Young calves may show reduced appetite and failure to thrive without dramatic acute illness. The gradual onset and chronic nature of mycoplasma disease often delays diagnosis until significant damage has occurred.

Common symptoms vary substantially depending on the body system primarily affected by Mycoplasma bovis. Respiratory disease presents as chronic coughing, persistent nasal discharge, labored breathing, and progressive weight loss despite treatment attempts. Ear infections, particularly common in young calves, cause head tilting, ear drooping, discharge from the ear canal, and signs of pain when the ear base is touched. Arthritis manifests as joint swelling, lameness affecting one or more limbs, reluctance to rise, and progressive loss of body condition. Mastitis causes abnormal milk appearance, udder swelling, and in severe cases signs of systemic illness.

Behavioral changes associated with Mycoplasma bovis infection reflect both direct disease effects and chronic illness impacts. Calves with ear infections frequently shake their heads, rub their ears against objects, and may appear disoriented due to inner ear involvement affecting balance. Chronic pneumonia cases show persistent depression, reduced activity, and separation from healthy penmates. Animals with arthritis demonstrate obvious reluctance to move, difficulty rising, and preference for lying down. Affected cattle often show progressive appetite decline and failure to thrive despite adequate feed availability.

Physical signs of Mycoplasma bovis infection help differentiate this pathogen from other disease causes. Respiratory cases develop a characteristic chronic pneumonia with firm lung consolidation, often affecting multiple lung lobes and persisting despite antimicrobial treatment. Joint infections produce obvious swelling of affected joints, most commonly the stifle, hock, carpus, and fetlock, with thickened joint capsules and restricted range of motion. Ear infections may show visible discharge and the drooped ear posture of middle ear involvement. Affected animals typically demonstrate poor body condition reflecting the chronic wasting nature of mycoplasmosis.

Symptom progression in Mycoplasma bovis disease follows a characteristic chronic pattern that distinguishes it from acute bacterial infections. Initial mild respiratory signs fail to resolve with standard treatment and gradually worsen over weeks to months. Arthritis cases show progressive joint destruction with increasing lameness despite therapy. Secondary complications develop as chronic illness compromises overall health, with affected animals becoming increasingly debilitated. Without effective intervention, many cases progress to a point where treatment is futile and humane euthanasia becomes necessary.

Emergency symptoms requiring immediate intervention include severe respiratory distress in animals with chronic mycoplasma pneumonia indicating acute deterioration or secondary bacterial infection. Recumbency due to severe arthritis or systemic illness represents a crisis point requiring immediate veterinary assessment. Calves showing neurological signs including circling, head tilt, and loss of balance may have inner ear or central nervous system involvement requiring urgent evaluation. Any animal showing rapid clinical deterioration after a prolonged course of chronic mycoplasma disease requires immediate veterinary attention for assessment and potentially humane euthanasia consideration.

Clinical examination for Mycoplasma bovis should consider this organism whenever cattle present with chronic respiratory disease unresponsive to standard treatment, arthritis particularly in young animals, ear infections in calves, or mastitis that spreads rapidly through a milking herd. Physical examination findings of chronic pneumonia with firm lung consolidation, swollen joints, or ear pathology suggest mycoplasmal involvement. A history of treatment failure with antimicrobials that would typically resolve bacterial respiratory disease heightens suspicion. The pattern of disease within a herd, including concurrent respiratory, joint, and ear problems, provides important diagnostic context.

Diagnostic testing for Mycoplasma bovis requires specialized laboratory procedures due to the organism's unique characteristics. Culture remains the gold standard but requires specialized media, extended incubation periods of up to two weeks, and expertise in recognizing the characteristic fried egg colony morphology. Polymerase chain reaction testing offers rapid and sensitive detection from clinical samples including nasal swabs, joint fluid, milk, and tissues. Serologic testing can identify exposed animals but cannot distinguish past from current infection and is complicated by the antigenic variation that characterizes mycoplasmas. Bulk tank milk PCR provides a useful herd-level screening tool for dairy operations.

Differential diagnosis for the various manifestations of Mycoplasma bovis includes multiple other pathogens and conditions. Chronic respiratory disease requires differentiation from other causes of pneumonia including Pasteurella, Histophilus, and viral agents, as well as lung abscess and chronic aspiration pneumonia. Arthritis must be distinguished from other causes of joint infection including Histophilus somni, Trueperella pyogenes, and navel ill, as well as non-infectious causes such as trauma and osteochondrosis. Ear infections in calves may also result from other bacterial pathogens. Mastitis caused by Mycoplasma must be differentiated from environmental and contagious mastitis pathogens.

Herd-level diagnostics support Mycoplasma bovis control programs through systematic identification of infected animals and monitoring of herd status. In dairy herds, regular bulk tank milk testing identifies herds shedding Mycoplasma, triggering individual cow testing to identify and remove infected animals. In beef operations, diagnostic investigation of chronic respiratory disease cases and arthritis should routinely include mycoplasma testing. Necropsy examination of animals that die or are euthanized provides valuable diagnostic specimens and characterizes disease distribution. Surveillance testing of apparently healthy animals can identify subclinical carriers before they transmit infection.

Emergency and immediate treatment for severe Mycoplasma bovis disease focuses on supportive care and pain management while initiating antimicrobial therapy, though expectations for treatment success should be tempered by the characteristically poor response of mycoplasmal infections. Severely debilitated animals require assessment of prognosis and quality of life, as many chronic cases have progressed beyond the point where treatment can provide meaningful benefit. Animals with severe respiratory distress, complete inability to rise due to arthritis, or advanced systemic illness may be best served by humane euthanasia rather than prolonged ineffective treatment.

Medical management of Mycoplasma bovis infection centers on antimicrobial selection from the limited classes that demonstrate activity against cell wall-deficient organisms. Macrolides including tulathromycin, tilmicosin, and gamithromycin represent first-line options for respiratory disease cases. Fluoroquinolones such as enrofloxacin and danofloxacin provide alternative coverage. Tetracyclines including oxytetracycline and chlortetracycline have some efficacy. Importantly, beta-lactam antibiotics including penicillins and cephalosporins have no activity against Mycoplasma due to the absence of a cell wall target. Even with appropriate antimicrobial selection, treatment success rates remain disappointing, particularly for chronic cases with established tissue damage.

Surgical intervention for Mycoplasma bovis disease is generally not applicable, as the diffuse nature of pneumonia, multiple joint involvement, and middle ear infections do not lend themselves to surgical correction. Joint lavage has been attempted for arthritis cases but provides minimal benefit given the ongoing infection and inflammation. The chronicity of mycoplasma disease and poor overall prognosis typically preclude investment in surgical approaches. Focus remains on medical management and supportive care, with recognition that treatment limitations may necessitate humane euthanasia for severely affected animals.

Supportive care for Mycoplasma bovis cases includes anti-inflammatory therapy to reduce pain and inflammation, particularly important for arthritis cases where joint pain significantly impacts welfare. Non-steroidal anti-inflammatory drugs such as meloxicam or flunixin provide analgesia and reduce inflammatory damage. Nutritional support encourages intake in animals with reduced appetite, and housing in comfortable, well-bedded areas with easy access to feed and water facilitates recovery. Separating affected animals from healthy penmates reduces transmission while allowing closer monitoring and care.

Herd treatment considerations for Mycoplasma bovis focus on preventing spread rather than mass treatment of infected animals. Unlike acute bacterial outbreaks where metaphylaxis may reduce disease incidence, the chronic nature of mycoplasma infection and limited treatment efficacy make population-level antibiotic treatment less effective. Instead, management emphasizes identification and segregation or culling of infected animals to reduce transmission pressure. Environmental management including improved ventilation, reduced crowding, and enhanced biosecurity complements individual animal treatment efforts.

Treatment decisions for Mycoplasma bovis cases must realistically consider the guarded to poor prognosis associated with established infection. Animals identified early with mild disease may respond to aggressive antimicrobial therapy, but chronic cases with extensive lung damage, multiple joint involvement, or severe debilitation rarely recover sufficiently for productive life. Economic analysis often favors early culling of affected animals over prolonged treatment with limited success probability. Humane euthanasia should be considered promptly for animals with severe disease manifestations, chronic treatment-resistant infection, or poor quality of life due to pain and debilitation.

Recovery timeline for Mycoplasma bovis infection reflects the characteristically chronic nature of this disease. Unlike acute bacterial infections where clinical improvement occurs within days of appropriate treatment, mycoplasma cases that do respond often require weeks to months to show meaningful improvement. Even with apparent clinical recovery, many animals harbor persistent infection and may relapse during future stress events. Animals that recover from respiratory disease may retain permanent lung damage affecting future performance. Complete cure versus transition to a chronic carrier state is often difficult to determine.

Post-treatment care and monitoring for Mycoplasma bovis cases requires extended observation periods reflecting the prolonged disease course. Animals showing initial improvement should be monitored closely for weeks following treatment completion, watching for disease recurrence that indicates persistent infection. Weight gain and body condition provide objective measures of recovery progress. Respiratory cases should be monitored for chronic coughing or exercise intolerance suggesting residual lung damage. Animals with previous arthritis require observation for recurrent lameness. Recovered animals should be considered potential carriers capable of transmitting infection.

Prognosis factors in Mycoplasma bovis infection include disease duration before treatment, extent of tissue damage, presence of multiple body system involvement, and individual immune response capability. Early cases identified promptly and treated aggressively carry the best prognosis, though success rates remain modest compared to other bacterial infections. Chronic pneumonia with extensive lung consolidation, severe arthritis with joint destruction, or multiple affected sites indicate poor prognosis. Young animals may have somewhat better recovery potential than older cattle, but even juvenile cases often develop chronic disease.

Return to production considerations must account for the permanent impacts of Mycoplasma bovis infection on animal performance. Cattle surviving respiratory disease often show reduced lung capacity and impaired respiratory efficiency that limits performance, particularly under stress or during hot weather. Animals recovered from arthritis may show persistent joint abnormalities and mild lameness that affects mobility and comfort. Dairy cattle recovering from mastitis frequently show reduced production in affected quarters. Additionally, recovered animals may serve as chronic carriers and sources of infection for naive herdmates, complicating reintegration into general populations.

Vaccination protocols for Mycoplasma bovis prevention remain limited due to the lack of consistently effective commercial vaccines in most markets. Autogenous vaccines prepared from organisms isolated from affected herds have been used with variable success. The antigenic variation characteristic of mycoplasmas complicates vaccine development, as immunity to one variant may not protect against others. Research continues on improved vaccine candidates, but current control programs rely primarily on management interventions rather than vaccination. Operations in regions where commercial vaccines are available should consult with their veterinarian regarding appropriate use.

Biosecurity measures represent the primary defense against Mycoplasma bovis introduction into naive herds. Maintaining closed herds or implementing strict quarantine and testing protocols for all incoming animals prevents introduction through purchased cattle. Testing all potential additions using PCR or culture before permitting contact with resident animals identifies carriers before they can transmit infection. Avoiding common-source introductions, where multiple animals from sales or auction markets enter simultaneously, reduces the risk of introducing infected animals. Controlling fence-line contact with neighboring cattle and preventing entry of wildlife and stray animals closes other potential introduction pathways.

Nutritional prevention strategies focus on maintaining optimal immune function through adequate nutrition. While no specific nutritional interventions prevent Mycoplasma bovis infection, well-nourished cattle with adequate trace mineral and vitamin status mount more effective immune responses to all pathogens. Colostrum management ensuring adequate passive transfer of maternal antibodies provides calves with initial protection during the vulnerable early life period. Avoiding nutritional stress through consistent feed availability and appropriate diet transitions supports overall immune competence and disease resistance.

Management practices crucial for Mycoplasma bovis control focus heavily on calf rearing environments where transmission risk is highest. Pasteurizing or using milk replacer rather than feeding raw waste milk eliminates a major transmission pathway for mycoplasma mastitis strains. Individual calf housing during the early weeks of life prevents direct contact transmission between calves. Excellent ventilation in calf housing reduces respiratory pathogen accumulation. Strict sanitation of feeding equipment, housing, and personnel between calves prevents indirect transmission. Avoiding overcrowding and maintaining appropriate group sizes when calves are later commingled limits disease spread.

Quarantine and testing protocols support Mycoplasma bovis control through systematic identification and management of infected animals. New arrivals should be tested before introduction to established populations, with PCR testing of nasal swabs or other appropriate samples providing sensitive detection. In dairy herds, regular bulk tank surveillance identifies mycoplasma shedding, triggering individual cow testing to identify infected animals for segregation or culling. Eradication programs require repeated testing with removal of all positive animals, a potentially expensive undertaking justified by the long-term benefits of freedom from this difficult pathogen.

Daily management and monitoring for Mycoplasma bovis control requires vigilant observation for the subtle early signs that characterize this pathogen's disease presentations. Personnel should watch for chronic coughing, mild nasal discharge, reduced feed intake, ear drooping or head shaking in calves, and any lameness or joint swelling. Unlike acute respiratory pathogens, mycoplasma infections often develop gradually, making early detection challenging but critically important for treatment success. Documenting disease patterns and treatment responses helps identify mycoplasma involvement when cases fail to respond to standard therapies.

Housing and environmental management significantly impact Mycoplasma bovis transmission and disease expression. Calf housing should provide individual pens during early life to prevent direct contact transmission, with excellent ventilation to maintain air quality while avoiding drafts. All-in, all-out management of calf groups prevents older infected calves from transmitting to younger arrivals. Thorough cleaning and disinfection between calf groups reduces environmental contamination. Adult cattle housing should avoid overcrowding and ensure adequate ventilation to minimize respiratory disease pressure.

Herd health programs addressing Mycoplasma bovis require integration of biosecurity, surveillance, and response protocols. Working with a veterinarian to develop a mycoplasma control plan appropriate for the operation's risk profile ensures systematic attention to this pathogen. For dairy herds, protocols should address bulk tank monitoring frequency, individual cow testing procedures, and criteria for segregation or culling of positive animals. For beef operations, programs should emphasize quarantine and testing of introductions and appropriate diagnostic workup of chronic respiratory disease and arthritis cases.

Record keeping and monitoring systems support Mycoplasma bovis control through documentation of testing results, disease events, and treatment outcomes. Maintaining records of all animals tested and their results enables tracking of herd status over time and identification of infection sources during outbreak investigations. Treatment records documenting products used, duration, and outcomes help identify patterns of treatment failure suggestive of mycoplasma involvement. Disease surveillance data including morbidity rates, mortality causes, and chronic illness patterns reveal mycoplasma impacts and guide program adjustments.

Economic considerations in Mycoplasma bovis management weigh prevention and control costs against disease losses. Testing and biosecurity programs require ongoing investment but prevent the substantial losses associated with herd-wide outbreaks. Individual animal treatment decisions must consider the poor prognosis and low recovery rates when calculating expected returns from treatment investment. Culling of infected animals represents economic loss but prevents ongoing transmission and treatment costs. For dairies with mycoplasma mastitis, aggressive culling programs though expensive provide the only reliable path to eliminating infection and preventing continued spread through the milking herd.

All cattle breeds are susceptible to Mycoplasma bovis infection, with management and exposure factors rather than genetics determining disease risk. The pathogen infects beef and dairy cattle of all breed types with similar ability to cause disease. Holstein calves often appear prominently in disease reports largely due to the management practices common in dairy calf raising, including feeding of potentially contaminated waste milk and group housing that facilitates transmission. Feedlot cattle of all breeds face risk when mycoplasma circulates in the population.

Production type significantly influences Mycoplasma bovis disease patterns and primary manifestations. Dairy operations face distinct challenges with mycoplasma mastitis, a highly contagious udder infection that spreads through milking equipment and procedures, as well as respiratory and ear infections in calves. Beef feedlots commonly encounter chronic pneumonia cases, often as a component of the broader bovine respiratory disease complex, and arthritis in recently arrived cattle. Cow-calf operations with closed herds and minimal outside introductions may maintain freedom from mycoplasma but face risk when bringing in bulls or replacement females from infected sources.

Genetic selection for Mycoplasma bovis resistance is not currently available, as no genetic markers or breed differences in susceptibility have been identified. Selection focuses instead on general immune competence traits that may provide broad benefits against multiple pathogens. Breeding and selection decisions for cattle health emphasize overall robustness, structural soundness, and adaptation to production environment rather than pathogen-specific resistance. Until genetic tools for mycoplasma resistance become available, management-based prevention strategies remain the primary approach to protecting cattle from this challenging pathogen.

Commonly co-occurring conditions with Mycoplasma bovis include other respiratory pathogens that frequently participate in the bovine respiratory disease complex. Viral infections with IBR, BVDV, BRSV, and PI3 often precede or accompany mycoplasma pneumonia, creating respiratory tract damage that facilitates secondary infection. Other bacterial pathogens including Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni may co-infect with Mycoplasma bovis, complicating both diagnosis and treatment. Concurrent infections typically result in more severe disease than single-agent infections.

Conditions with similar symptoms to Mycoplasma bovis require careful differentiation for appropriate management. Chronic pneumonia from other bacterial causes, lung abscess, and chronic aspiration pneumonia produce similar respiratory presentations requiring diagnostic testing to distinguish. Arthritis in young cattle may also result from Histophilus somni, Trueperella pyogenes, navel ill sequelae, or trauma. Ear infections can occur with other bacterial pathogens, though mycoplasma remains the most common cause in calves. Mastitis caused by various contagious and environmental pathogens requires culture-based differentiation from mycoplasma.

Complications and sequelae of Mycoplasma bovis infection reflect the chronic and tissue-destructive nature of this pathogen. Chronic pneumonia cases develop permanent lung damage with fibrosis, adhesions, and reduced functional capacity that persists after apparent recovery. Arthritis causes progressive joint destruction with cartilage loss, bone changes, and chronic lameness that may never fully resolve. Ear infections can progress to involve the inner ear and brain, causing permanent vestibular damage with persistent head tilt and balance problems. Mastitis may result in permanent quarter loss even if systemic spread is prevented. The chronic carrier state that follows recovery enables potential disease recurrence and ongoing transmission risk.